Promo active - $85 off your first month. Start for just $395.
FuturHealth

Zepbound KwikPen PDP Landing

Zepbound KwikPen tirzepatide

FuturHealth Zepbound® KwikPen® Program

Zepbound® is FDA-approved tirzepatide for weight loss, taken once a week with the pre-filled KwikPen®.

$395/month

What's included:

  • Zepbound® KwikPen® (if prescribed)
  • Pen needles included with every shipment
  • Online Clinician Consultation
  • Ongoing Clinical Support
  • Nutrition Plan

If prescribed $395 first month, then auto-renews at $480/mo.

guarantee badge

100% Membership Satisfaction Guarantee**

If you don’t see progress with full adherence, we’ll refund your membership fees.

Review platform badge

Zepbound® (tirzepatide) activates two natural hormone receptors, GIP and GLP-1, that signal the areas of your brain that regulate appetite. That helps you feel full sooner, eat less, and stay in control of cravings. It’s a once-weekly injection with the pre-filled KwikPen®, so there’s no mixing or measuring. Pen needles are included with every shipment, so there’s nothing extra to buy.

  • $395 for Month 1 ($85 off), then auto renews at $480/month. Includes program membership and medication cost (any dose).
  • Notification: You will be notified via email at least 7 days before any price or period changes.
  • Cancellations and Refunds: To cancel or request a refund under our guarantee, call (888) 616-4783.
Subscribe Now

If prescribed $395 first month, then auto-renews at $480/mo.

*$395 first month ($85 off), then auto-renews at $480/mo. Includes program membership and medication cost (any dose).

**If you don't see change by the end of your program with full adherence, we will give you your membership fees (excluding medical related costs tied to clinicians and pharmacy fees) back. It’s that simple. To qualify you must complete your in-app check-ins each week of the program.

Side effects of Zepbound® may include possible thyroid tumors. See here for details.

†Individual results may vary based on starting weight and program adherence including but not limited to diet and exercise. In the SURMOUNT-1 trial, adults taking Zepbound® 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo.

Zepbound® and KwikPen® are registered trademarks of Eli Lilly and Company.